Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide + Dapagliflozin vs DPP-4i in T2DM with Albuminuria
NCT06611904Active, not recruiting
- Sponsor
- Attikon University Hospital
- Start
- Feb 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of dulaglutide and dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Attikon University Hospital. Primary endpoints: Urine Albumin-to-Creatinine Ratio at 12 months, Pulse Wave Velocity at 12 months and 2 more. Started Feb 2018; status: active, not recruiting.
02
Drugs
dulaglutidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06611904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611904.